Vaccination and malignant disease: promising therapeutic approach.
Immunotherapy of cancer is now entering its second century. Much of our understanding of the complex interaction between tumours and the host immune system has come about because of technological and immunobiological advances in very recent years. For some malignancies, such as bladder cancer and malignant melanoma, immunotherapy is becoming an accepted form of adjuvant therapy. However, for most types of cancer, immunotherapy remains experimental and the majority of surgeons will have had little experience of immunotherapy in the clinical setting. This review provides a background to the scientific basis of immunotherapy, how different forms of immunotherapy are delivered and how their effects are monitored.
McKechnie
A
A
Department of Surgery, University of Nottingham, NG7 2RD, UK. mckechnie@mac.com
Robins
R A
RA
Eremin
O
O
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines / Q000494:pharmacology / Q000627:therapeutic use; D016903:Drug Monitoring; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines